Jiya Sun
Suzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Efficacy and Safety of KRASG12C Inhibitor IBI351 Monotherapy in Patients With Advanced NSCLC: Results From a Phase 2 Pivotal Study.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: May 28, 2024
Baseline tumour vessel perfusion as a non-invasive predictive biomarker for immune checkpoint therapy in non-small-cell lung cancer.
Journal: BMJ oncology
Published: May 15, 2024
A tumor cornification and immune-infiltration-based scheme for anti-PD-1 plus chemotherapy response in advanced squamous cell lung carcinoma.
Journal: Med (New York, N.Y.)
Published: December 26, 2023
Classification of Tumor Immune Microenvironment According to Programmed Death-Ligand 1 Expression and Immune Infiltration Predicts Response to Immunotherapy Plus Chemotherapy in Advanced Patients With NSCLC.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: November 04, 2022
Sintilimab versus docetaxel as second-line treatment in advanced or metastatic squamous non-small-cell lung cancer: an open-label, randomized controlled phase 3 trial (ORIENT-3).
Journal: Cancer communications (London, England)
Published: December 15, 2021
Assessment of TMB, PD-L1, and lymphocyte to monocyte ratio as predictive potential in a phase Ib study of sintilimab in patients with advanced solid tumors.
Journal: American journal of cancer research
Published: June 16, 2021
Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: May 08, 2021
Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2).
Journal: Nature communications
Published: April 28, 2021
Cancer immune therapy with PD-1-dependent CD137 co-stimulation provides localized tumour killing without systemic toxicity.
Journal: Nature communications
Published: November 26, 2020
Combined strategies for effective cancer immunotherapy with a novel anti-CD47 monoclonal antibody.
Journal: Cancer immunology, immunotherapy : CII
Published: September 15, 2020
Showing 1-11 of 11
Last Updated: 09/26/2026